Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

Klogene (United States) | Researchclopedia

Back to institutions

Klogene (United States)

Boston, Massachusettscompany

24

Works

1,529

Citations

22

h-index

Top Research Topics

Bladder and Urothelial Cancer Treatments Statistical Methods in Clinical Trials Cancer Research and Treatments

Top Researchers

Richard M. Ransohoff Western University

509 works81,016 citationsh-index: 129

Recent Research

The proportional treatment effect: A metric that empowers and connects

Guoqiao Wang,Yijie Liao,et al.

20250 citations

Meta-analysis and systematic reviews

Parathyroid Disorders and Treatments

Immunotherapy and Immune Responses

Advanced Causal Inference Techniques

Enzyme Structure and Function

Genetic Syndromes and Imprinting

Parkinson's Disease Mechanisms and Treatments

Bacterial Genetics and Biotechnology

Multiple Sclerosis Research Studies

Richard A. Rudick Norwalk Hospital

324 works35,437 citationsh-index: 85

Raj S. Pruthi University of North Carolina at Chapel Hill

522 works13,765 citationsh-index: 60

Carmela R. Abraham Advantagene (United States)

180 works13,706 citationsh-index: 53

81 works12,153 citationsh-index: 21

Richard Bryce Henry Ford Health System

153 works5,851 citationsh-index: 29

LEGEND: A phase 1/2 study of detalimogene voraplasmid (EG-70), an intravesical monotherapy for patients with high-risk non–muscle-invasive bladder cancer (NMIBC).

Jen‐Jane Liu,Raj Satkunasivam,et al.

20250 citations

A Phase I/II Study of Detalimogene Voraplasmid Intravesical Monotherapy for Patients with High-Risk Non-Muscle Invasive Bladder Cancer

Félix Guerrero‐Ramos,Alexander Light,et al.

20250 citations

Preliminary results from LEGEND: A phase 2 study of detalimogene voraplasmid (EG-70), a novel, non-viral intravesical gene therapy for patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS).

John A. Taylor,Shreyas Joshi,et al.

20255 citations

A phase 1/2 study of detalimogene voraplasmid (EG-70) intravesical monotherapy for patients with high-risk non-muscle invasive bladder cancer (NMIBC).

Shreyas Joshi,Sam S. Chang,et al.

20250 citations

Mechanism of action and translation to the clinic of detalimogene voraplasmid (EG-70): A novel, investigational, non-viral immunotherapy for non-muscle-invasive bladder cancer (NMIBC).

Vikram M. Narayan,Yair Lotan,et al.

20250 citations